Related Experiment Video
Updated: Aug 15, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
[When and how to treat hepatitis B and C?]
1Toronto Western Hospital, Liver Clinic, 399 Bathurst St, Toronto, Ontario, M5ST 2S8, Canada. Isabelle.Pache@hospvd.ch
Pegylated interferon-alpha (PEG-IFN-alpha), lamivudine, and adefovir have improved chronic hepatitis B treatment. New therapies are being developed for chronic hepatitis C, aiming for better sustained virologic response rates.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Context:
- Chronic hepatitis B and C are significant global health concerns.
- Current treatments include pegylated interferon-alpha (PEG-IFN-alpha), lamivudine, adefovir, and ribavirin.
- Treatment efficacy for hepatitis C varies based on viral genotype and patient factors.
Purpose:
- To review the current therapeutic landscape for chronic viral hepatitis.
- To highlight advancements in antiviral therapies.
- To discuss the potential of combination therapies.
Summary:
- Pegylated interferon-alpha (PEG-IFN-alpha), lamivudine, and adefovir have enhanced chronic hepatitis B management.
- Lamivudine can reduce risks of decompensation and hepatocellular carcinoma in cirrhotic patients without resistance.
- Standard chronic hepatitis C therapy (PEG-IFN-alpha with ribavirin) achieves sustained virologic response in 20-80% of patients, influenced by multiple factors.
- Novel antiviral strategies are under investigation.
Impact:
- Improved patient outcomes for chronic hepatitis B.
- Potential for more effective combination therapies in the future.
- Ongoing research into novel antiviral strategies for hepatitis C.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
04:11Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
Related Concept Videos
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Cytomegalovirus Disease
Hepatitis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction